Theranostics is a groundbreaking topic that's reshaping how we diagnose and treat cancer. It's a cutting-edge approach in cancer care, combining diagnosing and treating cancer using the same molecular tools. Theranostics has the spotlight because it's delivering on a promise we've been chasing for years in cancer care, truly personalized targeted treatment with fewer side effects than traditional options.   Guests: Lindsay Williams, MBA, CNMT, R.T.(N)(CT)(ARRT) Pharmacy Sourcing Portfolio Executive Vizient   Setu Shah, MPH Sr. Associate, Intelligence Sg2   Janna Laton, MBA, CNMT, NMTCB(CT), R.T.(R)(N)(MR)(ARRT) Independent Contributor and SME   Host: Adam Fairbourn, MBA, CNMT Senior Director, Contract Services Vizient, Capital Equipment Solutions   Show Notes: [00:48 – 01:55] What it takes for a healthcare organization to implement Theranostics [01:56 – 04:04] Success stories solving for some of the access and workflow issues [04:05 – 05:11] Education and training programs needed to support demand for nuclear medicine specialists and technologists [05:12 – 07:54] What's driving that growth in the field [07:55 – 09:34] What’s most exciting about theranostics over the next five to 10 years [09:34– 10:08] Will Theranostics become the standard of care for more types of cancer than we see today [10:09 – 11:30] The future of cancer care and Theranostics [11:30– 12:03] What Vizient is doing on the Theranostics front   Links | Resources: Vizient article - https://www.vizientinc.com/insights/diagnostic-imaging Sg2 Perspectives Podcast: Transforming Cancer Care Delivery Sg2 Perspectives Podcast: Cell and Gene Therapy in Practice   Subscribe Today! Apple Podcasts Spotify YouTube RSS Feed